AVEFF (Avecho Biotechnology) Total Liabilities : $1.09 Mil (As of Dec. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Avecho Biotechnology Total Liabilities?

Avecho Biotechnology's Total Liabilities for the quarter that ended in Dec. 2024 was $1.09 Mil.

Avecho Biotechnology's quarterly Total Liabilities increased from Dec. 2023 ($0.63 Mil) to Jun. 2024 ($1.09 Mil) but then stayed the same from Jun. 2024 ($1.09 Mil) to Dec. 2024 ($1.09 Mil).

Avecho Biotechnology's annual Total Liabilities increased from Dec. 2022 ($0.62 Mil) to Dec. 2023 ($0.63 Mil) and increased from Dec. 2023 ($0.63 Mil) to Dec. 2024 ($1.09 Mil).

Avecho Biotechnology Total Liabilities Historical Data

The historical data trend for Avecho Biotechnology's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avecho Biotechnology Total Liabilities Chart

Avecho Biotechnology Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

0.53

0.51

0.62

0.63

1.09

Avecho Biotechnology Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Liabilities	Get a 7-Day Free Trial															0.62	1.16	0.63	1.09	1.09

Avecho Biotechnology Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Avecho Biotechnology's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.083	+	(0.009	+	0.0020000000000001
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	1.09

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	3.165	-	2.071
	=	1.09

Avecho Biotechnology's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.083	+	(0.009	+	0.0020000000000001
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	1.09

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	3.165	-	2.071
	=	1.09

Avecho Biotechnology Total Liabilities Related Terms

Thank you for viewing the detailed overview of Avecho Biotechnology's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Avecho Biotechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avecho Biotechnology Ltd (OTCPK:AVEFF) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

OEZ:Germany AVE:Australia

Address

Unit A8, 2A Westall Road, Clayton, Melbourne, VIC, AUS, 3168

Website

https://www.avecho.com.au

Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology Tocopheryl Phosphate Mixture (TPM), for the pharmaceutical, skincare, and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.

Avecho Biotechnology Headlines

From GuruFocus

Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia

By PRNewswire • 03-03-2025